# US 2001/0011098 A1 · Pharmaceutical composition for angiotensin II-mediated diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0011098 A1
- Document ID: US20010011098A1
- Status: Published application
- Kind: A1
- Application number: 09/783,579
- Filed: 2001-02-15
- Published: 2001-08-02
- Earliest claimed: 1993-06-07
- Assignees: Takeda Chemical Industries, Ltd.
- Inventors: Yoshiyuki Inada; Keiji Kubo
- Web page: https://patentgrep.com/patent/US20010011098A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/54: having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This invention relates to a pharmaceutical composition for angiotensin II-mediated diseases, which comprises a compound having angiotensin II antagonistic activity of the formula 1 wherein R1 is H or an optionally substituted hydrocarbon residue; R2 is an optionally esterified carboxyl group; R3 is a group capable of forming an anion or a group convertible thereinto; X is a covalent bond between the 2 phenyl rings or a spacer having a chain length of 1 to 2 atoms as the linear moiety between the adjoining phenylene group and phenyl group; n is 1 or 2; the ring A is a benzene ring having 1 or 2 optional substituents in addition to R2; and Y is a bond, —O—, —S(O)m— (wherein m is 0, 1 or 2) or —N(R4)— (wherein R4 is H or an optionally substituted alkyl group), or a pharmaceutically acceptable salt thereof in combination with a compound having diuretic activity or a compound having calcium antagonistic activity.

## Claims

### Claim 1

A pharmaceutical composition for angiotensin II-mediated diseases, which comprises a compound having angiotensin II antagonistic activity of the formula 16
wherein R1 is H or an optionally substituted hydrocarbon residue; R2 is an optionally esterified carboxyl group; R3 is a group capable of forming an anion or a group convertible thereinto; X is a covalent bond between the 2 phenyl rings or a spacer having a chain length of 1 to 2 atoms as the linear moiety between the adjoining phenylene group and phenyl group; n is 1 or 2; the ring A is a benzene ring having 1 or 2 optional substituents in addition to R2; and Y is a bond, —O—, —S(O)m— (wherein m is 0, 1 or 2) or —N(R4)— (wherein R is H or an optionally substituted alkyl group), or a pharmaceutically acceptable salt thereof in combination with a compound having diuretic activity or a compound having calcium antagonistic activity.

### Claim 2 (depends on 1)

The composition claimed in claim 1, in which R1 is an optionally substituted lower alkyl or lower cycloalkyl.

### Claim 3 (depends on 2)

The composition claimed in claim 2, in which R1 is ethyl.

### Claim 4 (depends on 1)

The composition claimed in claim 1, in which R1 is ethyl and Y is —O—.

### Claim 5 (depends on 1)

The composition claimed in claim 1, in which R2 is a group represented by the —CO—D″ (wherein D″ stands for hydroxyl or a lower alkoxy whose alkyl moiety is optionally substituted with hydroxyl, amino, halogen, lower alkanoyloxy, lower cycloalkanoyloxy, lower alkoxycarbonyloxy, lower cycloalkoxycarbonyloxy or lower alkoxy).

### Claim 6 (depends on 5)

The composition claimed in claim 5, in which R2 is a lower alkoxycarbonyl optionally substituted with cyclohexyloxycarbonyloxy.

### Claim 7 (depends on 1)

The composition of claim 1, in which R1 is an optionally substituted 5-7 membered monocyclic heterocyclic residue having a hydrogen atom capable of leaving as a proton.

### Claim 8 (depends on 7)

The composition claimed in claim 7, in which R3 is 17

### Claim 9 (depends on 8)

The composition claimed in claim 8, in which R3 is tetrazolyl.

### Claim 10 (depends on 8)

The composition claimed in claim 8, in which R3 is 2,5-dihydro-5-oxo-1,2,4-oxadiazole-3-yl.

### Claim 11 (depends on 1)

The composition claimed in claim 1, in which R2 is a lower alkoxycarbonyl substituted with cyclohexyloxycarbonyloxy and R3 is tetrazolyl.

### Claim 12 (depends on 1)

The composition of claim 1, in which R1 is a lower alkyl and Y is —O—, R2 is a lower alkoxycarbonyl substituted with cyclohexyloxycarbonyloxy, and R3 is tetrazolyl.

### Claim 13 (depends on 1)

The composition of claim 1, in which the compound represented by the formula (I) is (±)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate.

### Claim 14 (depends on 1)

The composition of claim 1, in which the compound represented by the formula (I) is 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid.

### Claim 15 (depends on 1)

The composition of claim 1, in which the compound represented by the formula (I) is pivaloyloxymethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate.

### Claim 16 (depends on 1)

The composition of claim 1, in which the compound represented by the formula (I) is 2-ethoxy-1-[[2′-(2,5-dihydro-5-oxo-1,2,4-oxadiazole-3-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid.

### Claim 17 (depends on 1)

The composition of claim 1, in which the compound having diuretic activity is a member selected from the group consisting of amiloride, chlorothiazide, hydrochloride, benzthiazide, ticrynafen, acetazolamide, aminophylline, cyclothiazide, trichloromethiazide, cyclopentiazide, hydrochlorothiazide, methyclothiazide, benthylhydrochlorothiazide, penfluthiazide, ethiazide, hydroflumethiazide, polythiazide, chlophenamide, chlorthalidone, cyclothiazide, bendroflumethiazide, meticrane, tripamide, metrazone, indapamide, quinethazone, furosemide, bumetanide, mefruside, azosemide, ethacrynic acid, sodium ethacrynate, piretanide, spironolactone, potassium canrenoate, quinethazone and triamterene.

### Claim 18 (depends on 1)

The composition of claim 1, in which the compound having calcium antagonistic activity is a member selected from the group consisting of diltiazem hydrochloride, teloridine hydrochloride, nicardipine hydrochloride, varnidipine hydrochloride, flunarizine hydrochloride, verapamil hydrochloride, manidipine hydrochloride, cinnarizine, nisoldipine, nitrendipine, nifedipine, nilvadipine, felodipine, nildipine, nimodipine, penidipine and benidipine.

### Claim 19 (depends on 1)

The composition of claim 1, in which the angiotensin II-mediated diseases include hypertension, cardiac insufficiency, ischemic peripheral circulation disturbances, myocardial ischemia, vein insufficiency, progressive cardiac insufficiency after myocardial infarction, diabetic nephritides, nephritis, arteriosclerosis, hyperaldosteronism, dermatosclerosis, glomerulosclerosis, renal insufficiency, diseases of central nervous system, sensory disturbances including Alzheimer's disease, deficiency of memory, depression, amnesia and senile dementia, anxiety neurosis, catatonia or indisposition, glaucoma, intraocular high tension.

### Claim 20

A method for the prophylaxis or treatment of angiotensin II-mediated diseases in a mammal in need thereof which comprises administering an effective amount of a compound having angiotensin II antagonistic activity represented by the formula (I) 18
wherein R1 is H or an optionally substituted hydrocarbon residue; R2 is an optionally esterified carboxyl group; R3 is a group capable of forming an anion or a group convertible thereinto; X is a covalent bond between the 2 phenyl rings or a spacer having a chain length of 1 to 2 atoms as the linear moiety between the adjoining phenylene group and phenyl group; n is 1 or 2; the ring A is a benzene ring having 1 or 2 optional substituents in addition to R2; and Y is a bond, —O—, —S(O)m— (wherein m is 0, 1 or 2) or —N(R4)— (wherein R4 is H or an optionally substituted alkyl group), or a pharmaceutically acceptable salt thereof in combination with an effective amount of a compound having diuretic activity or a compound having calcium antagonistic activity.
